BFRI: Biofrontera Company Value to Net Income

The Biofrontera Inc. (BFRI) price chart reflects the dynamics of a company with a P/E ratio of -2.00. The business relies on a closed photodynamic ecosystem, where the combination of specialized lamps and the Ameluz drug strictly locks clinics into the brand's technologies. Growth is driven by an aggressive capture of the US dermatology market, while optimized temperature-controlled hubs ensure supply chain continuity.

The analyst is assessing the credit risk of Biofrontera Inc. (BFRI) through the lens of debt load and profitability. Long-term Ameluz supply contracts and a steady patient flow ensure business resilience. On GURU.Markets, the company's price-to-earnings ratio is calculated as the market price divided by net income, determining the investment payback period. This indicator measures the fundamental overvaluation of the asset. It is critical for the investor to correlate this trend with strict FDA control over radiation standards.